| Updated coverage 01-20-22
ImmixBio (IMMX) Announces Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles For IMX-110
Good morning everyone,
Immix Biopharma, Inc. (NASDAQ: IMMX) Updated Coverage
Current price $5.71/share (as of 10:20 am EST 1-19-22)
IMMX looks to have back filled the pre-market gap up from $6.65/share. Now consolidating, could we see another afternoon run as we did yesterday? I think it’s a good possibility.
This morning IMMX announced interim safety data for their monotherapy Phase 1b/2a clinical trial of their lead product MX-110 for treatment of soft tissue sarcoma. The data indicated 100% completion of IMX-110 planned treatment cycles. Completion of planned treatment cycles refers to lack of drug-related interruptions (cycle delays, dose reductions, or dose interruptions due to drug toxicity).
The chart above compares IMX-110 with two FDA approved treatments for soft tissue sarcoma (we have included a brief discussion about soft tissue sarcoma below). Yondelis (PharmaMar) had 2020 revenues of $82M and Votrient (Novartis) had 2020 revenues of $653M. Clearly IMX-110 has superior results in their current stage of clinical trials.
IMX-110 and the IMMX SMARxT Platform seem to have the potential to develop into the SOC for soft tissue sarcoma given the fact that all study data thus far has shown superiority over competing compounds.
It is worthy to note that CEO, Dr. Ilya Rachman and CMO, Dr. Graham Ross both have experience at big pharma companies, not only in drug development, but in clinical trials where they have developed strong relationships in the clinical research industry.
The FDA has approved orphan drug designation for IMX-110 for the treatment of soft tissue sarcoma. The FDA has already approved rare pediatric disease designation to IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma.
Why IMMX will emerge as a leading biopharma stock:
New IPO, less than one month and still under the radar. Tiny float of 1.29M shares FDA Orphan Drug Designation FDA Rare Pediatric Disease Designation Novel oncology platform 15 patents and patents pending
Soft Tissue Sarcoma – Mayo Clinic Soft tissue sarcoma is a rare type of cancer that begins in the tissues that connect, support, and surround other body structures. This includes muscle, fat, blood vessels, nerves, tendons, and the lining of your joints.
More than 50 subtypes of soft tissue sarcoma exist. Some types are more likely to affect children, while others affect mostly adults. These tumors can be difficult to diagnose because they may be mistaken for many other types of growths.
Soft tissue sarcoma can occur anywhere in your body, but the most common types occur in the arms and legs, and in the abdomen. Surgical removal is the most common treatment, although radiation and chemotherapy also may be recommended — depending on the size, type, location, and aggressiveness of the tumor.
In general, cancer occurs when cells develop errors (mutations) in their DNA. The errors make cells grow and divide out of control. The accumulating abnormal cells form a tumor that can grow to invade nearby structures and the abnormal cells can spread to other parts of the body.
The type of cell that develops the genetic mutation determines what type of soft tissue sarcoma you have. For example, angiosarcoma begins in the lining of blood vessels, while liposarcoma arises from fat cells. Some types of soft tissue sarcoma include:
Angiosarcoma Dermatofibrosarcoma protuberans Epithelioid sarcoma Gastrointestinal stromal tumor (GIST) Kaposi’s sarcoma Leiomyosarcoma Liposarcoma Malignant peripheral nerve sheath tumor Myxofibrosarcoma Rhabdomyosarcoma Solitary fibrous tumor Synovial sarcoma Undifferentiated (pleomorphic sarcoma)
A risk of soft tissue sarcoma can be inherited from your parents. Genetic syndromes that increase your risk include hereditary retinoblastoma, Li-Fraumeni syndrome, familial adenomatous polyposis, neurofibromatosis, tuberous sclerosis, and Werner syndrome.
Chemical exposure. Being exposed to certain chemicals, such as herbicides, arsenic, and dioxin, may increase the risk of soft tissue sarcomas. Previous radiation treatment for other cancers can increase the risk of soft tissue sarcomas.
Original report below
Current Short Interest Data from Ortex.com as of Today (1-18-22) Cost to borrow avg. 225% APR, 100% utilization, 4.12M shares in float. Shares on Loan 670K.
A New Biopharma IPO, Immix Biopharma, Inc. (NASDAQ: IMMX) is Developing a Cancer Treatment That Kills Tumors
IMMX shares exploded two weeks ago and have maintained their higher pricing level. Why?
Good day everyone,
Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases.
Current price $5.84/share (as of market close 1-14-22)
We wanted to report on IMMX because it’s a new IPO in the biopharma sector and we want to explore their potential. The company announced that its shares began trading on the NASDAQ on December 16th and the IPO closed on December 20th with an offering of 4,200,000 shares of its common stock at a price of $5.00 per share, for gross proceeds of $21M.
The IPO is less that a month old and like often happens, the company shares declined over the first couple weeks to under $3.50/share. On January 3rd the company announced its lead product candidate, IMX-110 was granted Rare Pediatric Disease (RPD) designation by the Food and Drug Administration for the treatment of pediatric cancer.
IMMX shares more than doubled on the news, closed that day at $5.78/share and have remained near that price range since. A quick check of the IMMX stock chart will show the narrow range the shares have traded in for the past two weeks. Will the company value stay in this narrow range? I think not, I believe it’s going higher and what I say below is why.
Firstly, IMMX has a tiny share structure (7.5M outstanding and only 1.29M in the float) and insiders own 44.6% of the outstanding shares. Altium Capital Management is already in for an 8.27% stake. Competition for IMMX shares is intensifying.
As you read about the IMMX platform below, keep in mind that as of this writing, the company market value is less that $50M and compare that to other companies you know of with promising oncology treatments in development.
The second reason interest is growing in IMMX shares is their novel technology. IMMX is developing a new class of Tissue-Specific Therapeutics, or TSTx, which they believe will replace first-line therapies across a multitude of oncology indications.
That press release on January 3rd opened investor’s eyes to the IMMX cancer treatment technology. It’s new, novel, and quite amazing. As investor awareness grows, I believe the company will grow. To me, it seems like the FDA is already looking favorably toward the IMMX technology.
Their SMARxT Platform produces Tissue-Specific Therapies, which in cancer target all three components (1. cancer associated fibroblasts, 2. tumor-associated macrophages/immune cells, and 3. cancer itself), of the TME simultaneously, severing the critical lifelines between the tumor and its metabolic support.
You will learn more about the IMMX SMARxT Platform by visiting the resources I’ve listed below but, briefly, the IMMX technology starves a cancer tumor of the nutrients it needs to survive and grow, effectively killing it.
Just last Wednesday the company informed that “ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study.” That 50% is an impressive positive response rate. The data was generated after 1 cycle of treatment as a monotherapy in first line-therapy-resistant cancer – soft tissue sarcoma (STS) mouse study. Clinical treatment for STS, is a $3 billion market expected to grow to $6.5 billion by 2030.
Just to underscore the significance of the animal study above, Doxorubicin, a cancer treatment that IMMX may compete with, one with over $1B in revenues, had a response rate of 0% after 1 cycle of treatment in the same study.
Watch this short video that describes the function of their IMX-110 product and review the presentation linked below to familiarize yourself with this new approach to cancer treatment. I’m certain that savvy investors are doing it.
In the chart below you can see the three products in development at IMMX. As a part of your due diligence, you can review the company presentation.
IMMX was incorporated in California in 2012 so they have been developing their technology for a while. They also have a wholly owned Australian subsidiary, Immix Biopharma Australia Pty Ltd., to conduct various pre-clinical and clinical activities for the development of product candidates.
The potential for growth in value at IMMX is not only likely, but I also believe it could be exponential. As you study their SMARxT Platform you may understand why the competition for that tiny 1.29M share float is getting competitive.
Stay tuned for our full report on IMMX.
The Traders News Group |
